Steroids Induced Hyperglycemia: Its Effects and Management
Abstract
Steroids are medications that have been widely utilized for a number of ailments, both acute and chronic. The action of endogenous steroids, nuclear hormones that penetrate cell membranes to bind to certain glucocorticoid receptors in the cytoplasm of target cells to form glucocorticoid-receptor (GR) complexes, is mimicked by synthetic glucocorticoids. The translocated activated GR complex regulates DNA transcription in the cell nucleus. The main factor for drug-induced hyperglycemia is steroids. They not only worsen hyperglycemia in those who already have diabetes mellitus (DM), but they can also lead to DM in people who've not previously experienced it. Their incidence can reach up to 46% of patients, and their glucose levels can rise by up to 68% over baseline. Steroid effects are often narrow and reversible. Drug-induced diabetes is supposed to go away as steroid doses are decreased because their impact on endocrine metabolism returns to normal; however, this is often not the case. The synthesis of lipolysis, proteolysis, and hepatic glucose is increased by glucocorticoids (GCs) because they act as a substrate for oxidative stress metabolism. A wide range of medical conditions has been treated with GCs. Although steroid-induced hyperglycemia has been proven to be medically effective, it is still a widespread and potentially dangerous issue that must be taken into consideration when administering any GC dose. The most common scenario requires the use of insulin, particularly when the serum glucose level is greater than 200 mg/dL.
Keywords: Steroids, Glucocorticoids, Hyperglycemia, Resistance, Insulin
Keywords:
Steroids, Glucocorticoids, Hyperglycemia, Resistance, InsulinDOI
https://doi.org/10.22270/jddt.v13i6.6074References
Barnett K, Mercer S, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for healthcare, research, and medical education: a cross-sectional study. Lancet. 2012; 380:37-43. https://doi.org/10.1016/S0140-6736(12)60240-2
Guthrie B, Payne K, Alderson P, McMurdo M, Mercer S. Adapting clinical guidelines to take account of multimorbidity. BMJ. 2012; 345:e6341. https://doi.org/10.1136/bmj.e6341
Guthrie B, McCowan C, Davey P, Simpson CR, Dreischulte T, Barnett K. High risk prescribing in primary care patients particularly vulnerable to adverse drug events: cross sectional population database analysis in Scottish general practice. BMJ. 2011; 342:d3514. https://doi.org/10.1136/bmj.d3514
Bourgeois FT, Shannon MW, Valim C, Mandl KD. Adverse drug events in the outpatient setting: an 11-year national analysis. Pharmacoepidemiol Drug Safety. 2010; 19:901-10. https://doi.org/10.1002/pds.1984
Boyd C, Darer J, Boult C, Fried L, Boult L, Wu A. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases implications for pay for performance. JAMA. 2005; 294:716-24. https://doi.org/10.1001/jama.294.6.716
Hughes LD, McMurdo ME, Guthrie B. Guidelines for people not for diseases: the challenges of applying UK clinical guidelines to people with multimorbidity. Age Ageing. 2013; 42:62-9. https://doi.org/10.1093/ageing/afs100
Lorgunpai SJ, Grammas M, Lee DS, McAvay G, Charpentier P, Tinetti ME. Potential therapeutic competition in community-living older adults in the US: use of medications that may adversely affect a coexisting condition. PloS One. 2014; 9:e89447. https://doi.org/10.1371/journal.pone.0089447
American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity. Guiding principles for the care of older adults with multimorbidity: an approach for clinicians. J Am Geriatr Soc. 2012; 60:e1-25. https://doi.org/10.1111/j.1532-5415.2012.04188.x
https://study.com/academy/lesson/common-drug-disease-interactions.html
Trence DL. Management of patients on chronic glucocorticoid therapy: an endocrine perspective. Prim Care. 2003; 30:593-605. https://doi.org/10.1016/S0095-4543(03)00038-1
Ha Y, Lee KH, Jung S, Lee SW, Lee SK, Park YB. Glucocorticoid-induced diabetes mellitus in patients with systemic lupus erythematosus treated with high-dose glucocorticoid therapy. Lupus. 2011; 20:1027-1034. https://doi.org/10.1177/0961203311402246
Schäcke H, Döcke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther. 2002; 96:23-43. https://doi.org/10.1016/S0163-7258(02)00297-8
Geer EB, Islam J, Buettner C. Mechanisms of glucocorticoid-induced insulin resistance. Endocrinology & Metabolism Clinics of North America 2014; 43:75-102. https://doi.org/10.1016/j.ecl.2013.10.005
Hirsch IB, Paauw DS. Diabetes management in special situations. Endocrinol Metab Clin North Am. 1997; 26:631-645. https://doi.org/10.1016/S0889-8529(05)70271-1
Tamez-Perez HE, Gutierrez-Hermosillo H, Cedillo-Rodriguez JA, Mora-Torres N, Hernandez-Coria M, Gomez-de-Osio M. Tratamiento con insulina en el paciente hospitalizado con diabetes mellitus tipo 2 Única opción? Med Int Mex. 2007; 23:196-199.
Braithwaite SS, Barr WG, Rahman A, Quddusi S. Managing diabetes during glucocorticoid therapy. How to avoid metabolic emergencies. Postgrad Med. 1998; 104:163-166, 171, 175-176. https://doi.org/10.3810/pgm.1998.11.426
Donihi AC, Raval D, Saul M, Korytkowski MT, DeVita MA. Prevalence and predictors of corticosteroid-related hyperglycemia in hospitalized patients. Endocr Pract. 2006; 12:358-362. https://doi.org/10.4158/EP.12.4.358
Cağdaş DN, Paç FA, Cakal E. Glucocorticoid-induced diabetic ketoacidosis in acute rheumatic fever. J Cardiovasc Pharmacol Ther. 2008; 13:298-300. https://doi.org/10.1177/1074248408326609
Find out your risk of type 2 diabetes. Diabetes UK - Know Your Risk of Type 2 diabetes. Published: 2014. Accessed: Nov 10, 2022. Available at: http://riskscore.diabetes.org.uk/2013?gclid=CJfak7u60b4CFa3LtAodMl4AFw.
Tamez Perez HE, Gómez de Ossio MD, Quintanilla Flores DL, Hernández Coria MI, Tamez Peña AL, Cuz Pérez GJ, Proskauer Peña SL. Glucose disturbances in non-diabetic patients receiving acute treatment with methylprednisolone pulses. Rev Assoc Med Bras 2012; 58:125-128. https://doi.org/10.1590/S0104-42302012000100025
Clore JN, Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocr Pract 2009; 15:469-474. https://doi.org/10.4158/EP08331.RAR
Donihi AC, Raval D, Saul M, Korytkowski MT, DeVita MA. Prevalence and predictors of corticosteroid-related hyperglycemia in hospitalized patients. Endocr Pract 2006; 12:358-362. https://doi.org/10.4158/EP.12.4.358
Fong AC, Cheung NW. The high incidence of steroid-induced hyperglycaemia in hospital. Diabetes Res Clin Pract 2013; 99:277-280. https://doi.org/10.1016/j.diabres.2012.12.023
Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab 2002; 87:978-982. https://doi.org/10.1210/jcem.87.3.8341
Hwang JL, Weiss RE. Steroid-induced diabetes: a clinical and molecular approach to understanding and treatment. Diabetes Metab Res Rev 2014; 30:96-102. https://doi.org/10.1002/dmrr.2486
Guerra G, Ilahe A, Ciancio G. Diabetes and kidney transplantation: past, present, and future. Curr Diab Rep 2012; 12: 597-603. https://doi.org/10.1007/s11892-012-0306-3
Hjelmesaeth J, Hartmann A, Leivestad T, Holdaas H, Sagedal S, Olstad M, Jenssen T. The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int 2006; 69:588-595. https://doi.org/10.1038/sj.ki.5000116
Schäcke H, Döcke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002; 96:23-43. https://doi.org/10.1016/S0163-7258(02)00297-8
Perez A, Jansen-Chaparro S, Saigi I, Bernal-Lopez MR, Miñambres I, Gomez-Huelgas R. Glucocorticoid-induced hyperglycemia. J Diabetes 2014; 6:9-20. https://doi.org/10.1111/1753-0407.12090
Galofre JC. Manejo de los corticoides en la práctica clínica. Rev Med Univ Navarra 2009; 53:9-18. https://doi.org/10.15581/021.9148
Trence DL. Management of patients on chronic glucocorticoid therapy: an endocrine perspective. Prim Care 2003; 30: 593-605 https://doi.org/10.1016/S0095-4543(03)00038-1
Hirsch IB, Paauw DS. Diabetes management in special situations. Endocrinol Metab Clin North Am 1997; 26:631-645. https://doi.org/10.1016/S0889-8529(05)70271-1
Lukins MB, Manninen PH. Hyperglycemia in patients administered dexamethasone for craniotomy. Anesth Analg 2005; 100:1129-1133. https://doi.org/10.1213/01.ANE.0000146943.45445.55
Van Raalte DH, Ouwens DM, Diamant M. Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest. 2009; 39:81-93. https://doi.org/10.1111/j.1365-2362.2008.02067.x
Strohmayer EA, Krakoff LR. Glucocorticoids and cardiovascular risk factors. Endocrinol Metab Clin North Am 2011; 40:409-417. https://doi.org/10.1016/j.ecl.2011.01.011
Ruzzin J, Wagman AS, Jensen J. Glucocorticoid-induced insulin resistance in skeletal muscles: defects in insulin signalling and the effects of a selective glycogen synthase kinase-3 inhibitor. Diabetologia 2005; 48:2119-2130. https://doi.org/10.1007/s00125-005-1886-0
Perez A, Jansen-Chaparro S, Saigi I, Bernal-Lopez MR, Miñambres I, Gomez-Huelgas R. Glucocorticoid-induced hyperglycemia. J Diabetes 2014; 6:9-20. https://doi.org/10.1111/1753-0407.12090
Kasayama S, Tanaka T, Hashimoto K, Koga M, Kawase I. Efficacy of glimepiride for the treatment of diabetes occurring during glucocorticoid therapy. Diabetes Care 2002; 25:2359-2360. https://doi.org/10.2337/diacare.25.12.2359
Pichardo-Lowden AR, Fan CY, Gabbay RA. Management of hyperglycemia in the non-intensive care patient: featuring subcutaneous insulin protocols. Endocr Pract 2011; 17:249-260. https://doi.org/10.4158/EP10220.RA
Trence DL. Management of patients on chronic glucocorticoid therapy: an endocrine perspective. Prim Care 2003; 30:593-605. https://doi.org/10.1016/S0095-4543(03)00038-1
Published
Abstract Display: 887 
PDF Downloads: 619 PDF Downloads: 119 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.